Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics (n = 44)

From: Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

Median age, years (range) 71 (49–86)
Gender Male/female 19/25
Performance status  
0 24 (54.5)
1 14 (31.8)
2 4 (9.1)
≥3 2 (4.5)
Type of M protein n (%)  
IgG 22 (50.0)
IgA 10 (22.7)
IgD 1 (2.3)
BJP 10 (22.7)
No secreted 1 (2.3)
Durie-Salmon stage n (%)  
I 4 (9.1)
II 6 (13.6)
III 34 (77.3)
ISS stage n (%)  
1 10 (22.7)
2 11 (25.0)
3 23 (52.3)
No. genetic abnormalities of 13q deletion n (%)  
Yes 6 (13.6)
No 38 (86.4)
No. of stem cell transplantation n (%)  
Yes 15 (34.1)
No 29 (65.9)
No. of prior treatment regimens* n (%) 09 (20.5)  
1 16 (36.4)
2 7 (15.9)
≥3 12 (27.3)
Type of prior treatment regimens n (%)  
VAD 22 (25.9)
MP 19 (22.4)
HDD 10 (11.8)
Thalidomide 9 (10.6)
Stem cell transplantation 5 (5.9)
CP 5 (5.9)
ROAD 4 (4.7)
Cyclophosphamide alone 3 (3.5)
DEX pulse 2 (2.4)
MD 2 (2.4)
INF α-MP 2 (2.4)
CAD 1 (1.2)
RD 1 (1.2)
  1. CP: cyclophosphamide, prednisolone; CAD: cyclophosphamide, adriamycin, dexamethasone; DEX pulse: dexamethasone pulse therapy; MD: melphalan, dexamethasone; MP: melphalan, prednisolone; HDD: high dose dexamethasone; INF α: Interferon Alpha, RD: lenalidomide, dexamethasone; ROAD: MCNU, vincristine, melphalan, dexamethasone; VAD: vincristine, adriamycin, dexamethasone.
  2. *A regimen was defined as a single drug or combination therapy. Front-line therapy could be composed of more than one regimen.